AZN's COVID-19 Vaccine Shows Strong Responses, ACAD Fails CLARITY Study, BTAI Hits New High

RTTNews

21 Jul 2020 0 shares 1 views

AZN's COVID-19 Vaccine Shows Strong Responses, ACAD Fails CLARITY Study, BTAI Hits New High

RTTNews

Published 21 Jul 2020

Today's Daily Dose brings you news about disappointing results from ACADIA's major depressive disorder drug trial, AstraZeneca's promising results of COVID-19 vaccine candidate, BioXcel Therapeutics' SERENITY program, Immuron's update on its new therapeutic against campylobacter and ETEC (E-Coli) and very encouraging results of Synairgen's SNG001 in hospitalized COVID-19 patients.

Full Article

Related news coverage

These 25 investors are hunting for the next big fintech unicorn. Here's what founders should know before pitching them.

· Financial technology startups, commonly called fintech startups, seek to unseat some of the most powerful entrenched players..

Business Insider 20 Jul 2020

Moderna shares soar 18% after early coronavirus vaccine trial produces antibodies in all patients (MRNA)

· *Moderna stock surged as much as 18% on Wednesday after the company announced an early coronavirus vaccine trial produced..

Business Insider 15 Jul 2020

AZN's COVID-19 Vaccine Shows Strong Responses, ACAD Fails CLARITY Study, BTAI Hits New High

AZN's COVID-19 Vaccine Shows Strong Responses, ACAD Fails CLARITY Study, BTAI Hits New High

You might like

Related news coverage

These 25 investors are hunting for the next big fintech unicorn. Here's what founders should know before pitching them.

Moderna shares soar 18% after early coronavirus vaccine trial produces antibodies in all patients (MRNA)

Advertisement